annual EBIT:
-$108.11M+$24.56M(+18.51%)Summary
- As of today (September 15, 2025), TARS annual earnings before interest & taxes is -$108.11 million, with the most recent change of +$24.56 million (+18.51%) on December 31, 2024.
- During the last 3 years, TARS annual EBIT has fallen by -$94.33 million (-684.98%).
- TARS annual EBIT is now -7907.93% below its all-time high of -$1.35 million, reached on December 31, 2018.
Performance
TARS EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBIT:
-$18.25M+$4.80M(+20.83%)Summary
- As of today (September 15, 2025), TARS quarterly earnings before interest & taxes is -$18.25 million, with the most recent change of +$4.80 million (+20.83%) on June 30, 2025.
- Over the past year, TARS quarterly EBIT has increased by +$13.04 million (+41.67%).
- TARS quarterly EBIT is now -270.30% below its all-time high of $10.71 million, reached on March 31, 2021.
Performance
TARS quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBIT:
-$83.33M+$13.04M(+13.53%)Summary
- As of today (September 15, 2025), TARS TTM earnings before interest & taxes is -$83.33 million, with the most recent change of +$13.04 million (+13.53%) on June 30, 2025.
- Over the past year, TARS TTM EBIT has increased by +$62.00 million (+42.66%).
- TARS TTM EBIT is now -13065.09% below its all-time high of -$633.00 thousand, reached on September 30, 2019.
Performance
TARS TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
TARS EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +18.5% | +41.7% | +42.7% |
| 3 y3 years | -685.0% | -250.9% | -48.9% |
| 5 y5 years | -2415.3% | -459.2% | -1074.1% |
TARS EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -685.0% | +18.5% | -250.9% | +55.4% | -48.9% | +42.7% |
| 5 y | 5-year | -2415.3% | +18.5% | -270.3% | +55.4% | -2200.8% | +42.7% |
| alltime | all time | -7907.9% | +18.5% | -270.3% | +55.4% | <-9999.0% | +42.7% |
TARS EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$18.25M(-20.8%) | -$83.33M(-13.5%) |
| Mar 2025 | - | -$23.05M(+10.1%) | -$96.37M(-10.9%) |
| Dec 2024 | -$108.11M(-18.5%) | -$20.94M(-0.8%) | -$108.11M(-15.6%) |
| Sep 2024 | - | -$21.10M(-32.5%) | -$128.11M(-11.8%) |
| Jun 2024 | - | -$31.28M(-10.1%) | -$145.33M(+0.4%) |
| Mar 2024 | - | -$34.78M(-15.0%) | -$144.69M(+9.1%) |
| Dec 2023 | -$132.67M(+121.0%) | -$40.94M(+6.8%) | -$132.67M(+26.8%) |
| Sep 2023 | - | -$38.32M(+25.1%) | -$104.66M(+18.6%) |
| Jun 2023 | - | -$30.64M(+34.6%) | -$88.27M(+40.5%) |
| Mar 2023 | - | -$22.76M(+76.0%) | -$62.83M(+4.7%) |
| Dec 2022 | -$60.03M | -$12.94M(-41.0%) | -$59.99M(-3.0%) |
| Sep 2022 | - | -$21.93M(+321.8%) | -$61.85M(+10.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$5.20M(-73.9%) | -$55.95M(+28.7%) |
| Mar 2022 | - | -$19.92M(+34.6%) | -$43.47M(+238.6%) |
| Dec 2021 | -$13.77M(-49.0%) | -$14.80M(-7.7%) | -$12.84M(+34.9%) |
| Sep 2021 | - | -$16.04M(-320.2%) | -$9.52M(+162.8%) |
| Jun 2021 | - | $7.28M(-32.0%) | -$3.62M(-74.4%) |
| Mar 2021 | - | $10.71M(-193.4%) | -$14.17M(-47.5%) |
| Dec 2020 | -$27.00M(+528.2%) | -$11.48M(+13.2%) | -$27.00M(+62.6%) |
| Sep 2020 | - | -$10.14M(+210.8%) | -$16.61M(+134.0%) |
| Jun 2020 | - | -$3.26M(+54.1%) | -$7.10M(+85.1%) |
| Mar 2020 | - | -$2.12M(+95.4%) | -$3.83M(+123.4%) |
| Dec 2019 | -$4.30M(+218.4%) | -$1.08M(+71.2%) | -$1.72M(+171.2%) |
| Sep 2019 | - | -$633.00K | -$633.00K |
| Dec 2018 | -$1.35M | - | - |
FAQ
- What is Tarsus Pharmaceuticals, Inc. annual earnings before interest & taxes?
- What is the all time high annual EBIT for Tarsus Pharmaceuticals, Inc.?
- What is Tarsus Pharmaceuticals, Inc. annual EBIT year-on-year change?
- What is Tarsus Pharmaceuticals, Inc. quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Tarsus Pharmaceuticals, Inc.?
- What is Tarsus Pharmaceuticals, Inc. quarterly EBIT year-on-year change?
- What is Tarsus Pharmaceuticals, Inc. TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Tarsus Pharmaceuticals, Inc.?
- What is Tarsus Pharmaceuticals, Inc. TTM EBIT year-on-year change?
What is Tarsus Pharmaceuticals, Inc. annual earnings before interest & taxes?
The current annual EBIT of TARS is -$108.11M
What is the all time high annual EBIT for Tarsus Pharmaceuticals, Inc.?
Tarsus Pharmaceuticals, Inc. all-time high annual earnings before interest & taxes is -$1.35M
What is Tarsus Pharmaceuticals, Inc. annual EBIT year-on-year change?
Over the past year, TARS annual earnings before interest & taxes has changed by +$24.56M (+18.51%)
What is Tarsus Pharmaceuticals, Inc. quarterly earnings before interest & taxes?
The current quarterly EBIT of TARS is -$18.25M
What is the all time high quarterly EBIT for Tarsus Pharmaceuticals, Inc.?
Tarsus Pharmaceuticals, Inc. all-time high quarterly earnings before interest & taxes is $10.71M
What is Tarsus Pharmaceuticals, Inc. quarterly EBIT year-on-year change?
Over the past year, TARS quarterly earnings before interest & taxes has changed by +$13.04M (+41.67%)
What is Tarsus Pharmaceuticals, Inc. TTM earnings before interest & taxes?
The current TTM EBIT of TARS is -$83.33M
What is the all time high TTM EBIT for Tarsus Pharmaceuticals, Inc.?
Tarsus Pharmaceuticals, Inc. all-time high TTM earnings before interest & taxes is -$633.00K
What is Tarsus Pharmaceuticals, Inc. TTM EBIT year-on-year change?
Over the past year, TARS TTM earnings before interest & taxes has changed by +$62.00M (+42.66%)